Second Sight Medical Products Inc. (NASDAQ:EYES) shares rose 6.6% on Wednesday . The stock traded as high as $3.68 and last traded at $3.53, with a volume of 628,781 shares trading hands. The stock had previously closed at $3.31.

Separately, Zacks Investment Research cut Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Monday, April 4th.

The firm’s 50-day moving average price is $3.76 and its 200-day moving average price is $4.65. The company’s market capitalization is $147.75 million.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. During the same period in the prior year, the firm earned ($0.12) EPS. The company earned $1.05 million during the quarter, compared to analyst estimates of $1.38 million. Second Sight Medical Products’s quarterly revenue was down 38.2% compared to the same quarter last year. Equities research analysts expect that Second Sight Medical Products Inc. will post ($0.65) earnings per share for the current fiscal year.

In related news, Chairman Robert J. Greenberg sold 8,571 shares of the business’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total value of $35,141.10. Following the sale, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Robert J. Greenberg sold 8,223 shares of the business’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $5.27, for a total value of $43,335.21. Following the completion of the sale, the chairman now directly owns 181,134 shares in the company, valued at approximately $954,576.18. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC acquired a new stake in shares of Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products comprises 2.5% of Zeke Capital Advisors LLC’s portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned about 1.38% of Second Sight Medical Products as of its most recent filing with the SEC.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.